Sanofi Opens Continuous Biomfg Facility in Massachusetts; Opens New UK HQ
Sanofi has opened a new digital continuous biomanufacturing facility in Framingham, Massachusetts and separately a new site for its UK headquarters.
The new facility is part of Sanofi’s cross-functional biologics hub in Framingham and uses intensified, continuous processing in an integrated digitally powered facility. The facility will manufacture biologics for the company’s Specialty Care portfolio. Successful process qualification runs were completed in the third quarter 2019.
The new facility features technology that connects the production process with research and development. The Framingham campus offers co-location of infrastructure and activities from early-stage research and process development through clinical and commercial manufacturing, including enabling functions of quality control and compliance, regulatory, engineering, supply chain, and learning and development.
Framingham is the latest biologics manufacturing facility among a number of pilots, which are being accelerated across the Sanofi network at other legacy plants. Beyond Framingham, Sanofi intends to move forward with digital transformation initiatives in Toronto, Canada; Suzano, Brazil; Waterford, Ireland; Sisteron, France; and Geel, Belgium.
In a separate development, Sanofi has opened its new UK headquarters in Reading, Berkshire, United Kingdom. The new 70,000-square-foot office facility marks a £37 million ($48 million) investment for Reading, which Sanofi says will be the new base for 500 of its 1,200 employees in the UK.
In opening the new headquarters, Sanofi consolidated its Guildford, Oxford and Maidenhead offices to provide a cross-collaborative working environment. Sanofi says it is actively seeking to recruit at least 50 new roles in the coming months, in addition to 10 graduate students via its new Aspiring Leaders graduate program.